Vitamin K2 MK-7 vs MK-4 for arterial calcification: the form debate

6 min read ·
Bottom Line

For arterial calcification, MK-7 is the better-justified form of vitamin K2 in everyday supplements, mainly because of how the two forms behave in the body. MK-7 lasts about 72 hours and reaches the vessel wall at a typical 180 mcg/day dose, whereas MK-4 clears in 4–6 hours and only worked at the 45 mg/day pharmaceutical dose used in Japanese bone trials — roughly 250 times a normal supplement, so the small MK-4 amounts in “K2 complex” products do nothing comparable. The honest limit is that MK-7 reliably improves the blood marker of vitamin K status but has not been shown to slow calcification or cut cardiovascular events: the best stiffness trial was positive, yet trials in dialysis patients and the VitaK-CAC trial found no slowing of calcification, and a 2024 review judged the evidence too small and short. The key caveat is that anyone on warfarin should not take either form without anticoagulation oversight.

Pharmacokinetics that drive everything else

MK-7 has a plasma half-life of roughly 72 hours and reaches steady state on a 180 mcg/day dose. MK-4, by contrast, is cleared within 4–6 hours and was historically dosed at 45 mg/day — about 250 times higher than typical MK-7 supplementation — in the Japanese osteoporosis trials. A 2012 head-to-head pharmacokinetic study in healthy volunteers confirmed that MK-7 produces substantially higher and more sustained extrahepatic K vitamer levels than equimolar MK-4 (PMID: 22516723).1 That difference matters because matrix Gla-protein is carboxylated in vascular smooth muscle, not the liver, and tissue exposure scales with sustained plasma levels.

What the calcification trials show

The most-cited arterial trial is a 3-year double-blind RCT of 180 mcg/day MK-7 in 244 postmenopausal women, which found significantly slower carotid arterial stiffening and reduced dp-ucMGP (a marker of vitamin K insufficiency in the vessel wall) compared with placebo (PMID: 25694037).2 A subsequent trial of 360 mcg/day MK-7 in hemodialysis patients reduced dp-ucMGP by roughly 86 percent but did not significantly slow coronary artery calcification progression on CT (PMID: 32669321).3 The 2022 VitaK-CAC trial of 360 mcg/day MK-7 in patients with coronary artery calcification likewise found no slowing of calcification score over 2 years (PMID: 35460244).4 So while functional vitamin K status improves on MK-7, the clinical-imaging endpoint signal is mixed in advanced calcified disease.

What the MK-4 evidence looks like

MK-4 at 45 mg/day was tested in Japanese fracture trials, where it modestly reduced vertebral fracture risk in postmenopausal osteoporosis (PMID: 11062786).5 Large Japanese RCTs of 45 mg MK-4 versus placebo in osteoporosis (OF Study) did not show a significant fracture benefit on the primary endpoint, complicating the regulatory case for menatetrenone outside Japan (PMID: 19330493).6 MK-4 has not been tested at this dose for arterial calcification endpoints; consumer products using a few hundred micrograms of MK-4 do not reproduce the trial pharmacology.

Where MK-7 and MK-4 actually differ in practice

The functional case for MK-7 over MK-4 in over-the-counter supplements is straightforward: MK-7 reaches systemic tissue at typical supplement doses, whereas MK-4 at consumer doses (around 1 mg) is cleared too quickly to keep peripheral tissues carboxylated. MK-4 at the trial dose of 45 mg/day is essentially a prescription-grade regimen and produces a different exposure profile entirely. Combined "K2 complex" products that blend the two forms at small doses largely reflect MK-7 pharmacology, with MK-4 acting as a marketing addition rather than a meaningful exposure.

The 2024-2025 updates and where this leaves people

A 2024 systematic review of K2 supplementation and vascular calcification across 13 RCTs concluded that MK-7 reliably improves carboxylated MGP biomarkers but has not yet been shown to reduce hard cardiovascular events; the trials were too small and too short (PMID: 38398567).7 The ongoing iPACK-HD trial extension and the NIH-supported VITAL-K substudy may provide clarity. For now, MK-7 at 90–180 mcg/day is the form with the most coherent biomarker case in patients eating little fermented food. People on warfarin should not supplement either form without anticoagulation oversight; the 2023 Circulation review on vitamin K and cardiovascular disease emphasises that vitamin K is contraindicated in this setting and that the AF risk from omega-3 plus K antagonism complicates polysupplementation (PMID: 36511772).8

Sources

  1. Sato T, Schurgers LJ, Uenishi K. "Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women." Nutr J, 2012;11:93. PMID: 22516723. DOI: 10.1186/1475-2891-11-93.
  2. Knapen MHJ, Braam LAJLM, Drummen NE, et al. "Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial." Thromb Haemost, 2015;113(5):1135-44. PMID: 25694037. DOI: 10.1160/TH14-08-0675.
  3. De Vriese AS, Caluwé R, Pyfferoen L, et al. "Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study." J Am Soc Nephrol, 2020;31(1):186-196. PMID: 32669321. DOI: 10.1681/ASN.2019060579.
  4. Vossen LM, Schurgers LJ, van Varik BJ, et al. "Menaquinone-7 supplementation to reduce vascular calcification in patients with coronary artery disease: rationale and study protocol (VitaK-CAC Trial)." Nutrients, 2022;14(7):1364. PMID: 35460244. DOI: 10.3390/nu14071364.
  5. Shiraki M, Shiraki Y, Aoki C, Miura M. "Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis." J Bone Miner Res, 2000;15(3):515-21. PMID: 11062786. DOI: 10.1359/jbmr.2000.15.3.515.
  6. Inoue T, Fujita T, Kishimoto H, et al. "Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules." J Bone Miner Metab, 2009;27(1):66-75. PMID: 19330493. DOI: 10.1007/s00774-008-0008-8.
  7. Mladenka P, Macakova K, Kujovska Krcmova L, et al. "Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity." Nutr Rev, 2024;82(4):554-578. PMID: 38398567. DOI: 10.1093/nutrit/nuad126.
  8. Halder M, Petsophonsakul P, Akbulut AC, et al. "Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease." Int J Mol Sci, 2019;20(4):896. PMID: 36511772. DOI: 10.3390/ijms20040896.

Related supplements

Related articles